Mini-review: Bmx kinase inhibitors for cancer therapy

Recent Patents on Anti-Cancer Drug Discovery

Volumn 8, Issue 3, 2013, Pages 228-238

  Jarboe, John S ^a,b   Dutta, Shilpa ^b   Velu, Sadanandan E ^b   Willey, Christopher D ^a,b,c  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Bmx; Breast cancer; Btk; Etk; Glioblastoma; Kinase inhibitor; Lung cancer; Prostate cancer; Tec

Indexed keywords

1,3 CYCLOPENTADIONE DERIVATIVE; 2 CYANO N (2,5 DIBROMOPHENYL) 3 HYDROXYCROTONAMIDE; ACACIA NILOTICA EXTRACT; AVL 292; BMX KINASE INHIBITOR; BORTEZOMIB; CANERTINIB; CYSTEINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; IBRUTINIB; N [4 (3 BROMOANILINO) 6 QUINAZOLINYL]ACRYLAMIDE; PROTEIN KINASE INHIBITOR; PYRROLO [2, 3 D] PYRIMIDINE DERIVATIVE; SHORT HAIRPIN RNA; TOZASERTIB; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT; XANTHOHUMOL;

AMINO ACID SEQUENCE; ANTIANGIOGENIC THERAPY; BREAST CANCER; CANCER STEM CELL; CANCER THERAPY; CELL PROLIFERATION; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; DRUG TARGETING; ENZYMATIC ASSAY; GENE SILENCING; GLIOBLASTOMA; HUMAN; IC 50; LARGE CELL LYMPHOMA; LEUKEMIA; LUNG CANCER; LUNG SMALL CELL CANCER; NONHUMAN; PATENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATENTS AS TOPIC; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION;

EID: 84888020497     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/15748928113089990043     Document Type: Review

References (66)

1. Smith CI, Islam TC, Mattsson PT, Mohamed AJ, Nore BF, Vihinen M. The Tec family of cytoplasmic tyrosine kinases: Mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. Bioessays 2001; 23(5): 436-46.
2. Horwood NJ, Urbaniak AM, Danks L. Tec family kinases in inflammation and disease. Int Rev Immunol 2012; 31(2): 87-103.
3. Qiu Y, Kung HJ. Signaling network of the Btk family kinases. Oncogene 2000; 19(49): 5651-61.
4. Takesono A, Finkelstein LD, Schwartzberg PL. Beyond calcium: New signaling pathways for Tec family kinases. J Cell Sci 2002; 115(Pt 15): 3039-48.
5. Wen X, Lin HH, Shih HM, Kung HJ, Ann DK. Kinase activation of the non-receptor tyrosine kinase Etk/BMX alone is sufficient to transactivate STAT-mediated gene expression in salivary and lung epithelial cells. J Biol Chem 1999; 274(53): 38204-10.
6. Guryanova OA, Wu Q, Cheng L, Lathia JD, Huang Z, Yang J, et al. Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell 2011; 19(4): 498-511.
7. Kaukonen J, Lahtinen I, Laine S, Alitalo K, Palotie A. BMX tyrosine kinase gene is expressed in granulocytes and myeloid leukaemias. Br J Haematol 1996; 94(3): 455-60.
8. Mano H. Tec family of protein-tyrosine kinases: An overview of their structure and function. Cytokine Growth Factor Rev 1999; 10(3-4): 267-80.
9. Mueller C, August A. Attenuation of immunological symptoms of allergic asthma in mice lacking the tyrosine kinase ITK. J Immunol 2003; 170(10): 5056-63.
10. Schaeffer EM, Yap GS, Lewis CM, Czar MJ, McVicar DW, Cheever AW, et al. Mutation of Tec family kinases alters T helper cell differentiation. Nat Immunol 2001; 2(12): 1183-8.
11. Fowell DJ, Shinkai K, Liao XC, Beebe AM, Coffman RL, Littman DR, et al. Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD4+ T cells. Immunity 1999; 11(4): 399-409.
12. Lin TA, McIntyre KW, Das J, Liu C, O'Day KD, Penhallow B, et al. Selective Itk inhibitors block T-cell activation and murine lung inflammation. Biochemistry 2004; 43(34): 11056-62.
13. Lo HY. Itk inhibitors: A patent review. Expert Opin Ther Pat 2010; 20(4): 459-69.
14. Smith CI, Bäckesjö CM, Berglöf A, Brandén LJ, Islam T, Mattsson PT, et al. X-linked agammaglobulinemia: Lack of mature B lineage cells caused by mutations in the Btk kinase. Springer Semin Immunopathol 1998; 19(4): 369-81.
15. Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large Bcell lymphoma. Nature 2010; 463(7277): 88-92.
16. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010; 107(29): 13075-80.
17. Bagheri-Yarmand R, Mandal M, Taludker AH, Wang RA, Vadlamudi RK, Kung HJ, et al. Etk/Bmx tyrosine kinase activates Pak1 and regulates tumorigenicity of breast cancer cells. J Biol Chem 2001; 276(31): 29403-9.
18. Chen KY, Huang LM, Kung HJ, Ann DK, Shih HM. The role of tyrosine kinase Etk/Bmx in EGF-induced apoptosis of MDA-MB-468 breast cancer cells. Oncogene 2004; 23(10): 1854-62.
19. Cohen I, Maoz M, Turm H, Grisaru-Granovsky S, Maly B, Uziely B, et al. Etk/Bmx regulates proteinase-activated-receptor1 (PAR1) in breast cancer invasion: Signaling partners, hierarchy and physiological significance. PLoS One 2010; 5(6): e11135.
20. Dai B, Kim O, Xie Y, Guo Z, Xu K, Wang B, et al. Tyrosine kinase Etk/BMX is up-regulated in human prostate cancer and its overexpression induces prostate intraepithelial neoplasia in mouse. Cancer Res 2006; 66(16): 8058-64.
21. Dai B, Chen H, Guo S, Yang X, Linn DE, Sun F, et al. Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Cancer Res 2010; 70(13): 5587-96.
22. Hart JR, Liao L, Yates JR, Vogt PK. Essential role of Stat3 in PI3K-induced oncogenic transformation. Proc Natl Acad Sci USA 2011; 108(32): 13247-52.
23. Vogt PK, Hart JR. PI3K and STAT3: A new alliance. Cancer Discov 2011; 1(6): 481-6.
24. Rajantie I, Ekman N, Iljin K, Arighi E, Gunji Y, Kaukonen J, et al. Bmx tyrosine kinase has a redundant function downstream of angiopoietin and vascular endothelial growth factor receptors in arterial endothelium. Mol Cell Biol 2001; 21(14): 4647-55.
25. Honigberg, L., Verner, E. J., Buggy, J. J., Loury, D. J., Chen, W. Inhibitors of Bmx non-receptor tyrosine kinase. US20120184013 (2012).
26. Singh, J., Ghosh, S., Kluge, A. F., Petter, R. C., Tester, R. W. Heteroaryl compounds and uses thereof. US20100016296 (2010).
27. Buser-Doepner, C. A. Kinase inhibition and anticancer therapy. US20090105270 (2009).
28. John, G., Babish, J. S. B., Anu, D., Amy, J. H., Veera, K., Linda, M. P., Matthew, L. T. Protein kinase modulation by hops and Acacia products. US8263139 (2012).
29. Tripp, M. L., Babish, J. G., Bland, J. S., Konda, V., Desai, A., Darland, G., Carroll, B. J., Traub, J. S., Pacioretty, L. M., Emma, D. Substituted 1, 3-cyclopentadione multi-target protein kinase modulators of cancer and angiogenesis. US20100137449 (2010).
30. Nagle, A., Gray, N. S, Liu, Y., Ren, P., Sim, T., You, S. Substitued pyrrolo[2, 3-D]pyrimidines and compositions as protein kinase inhibitors. US8183248 (2012).
31. Brophy, C., Lander, C. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition. US20120263680 (2012).
32. Hallahan, D. E., Willey, C. D. Bmx mediated signal transduction in irradiated vascular endothelium. US8129356 (2012).
33. Lee Honigberg, E. V., Zhengying, P. Inhibitors of bruton's tyrosine kinase. US7825118 (2010).
34. Joseph, B. W. C., Lee Honigberg, D. L., Erik, V. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors. EP2307025 (2011).
35. Harrison C. Trial watch: BTK inhibitor shows positive results in B cell malignancies. Nat Rev Drug Discov 2012; 11(2): 96.
36. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2012. [Epub ahead of print].
37. Brown JR, Sharman JP, Harb WA, Kelly KR, Schreeder MT, Sweetenham JW, et al. Phase Ib trial of AVL-292, a covalent inhibitor of Bruton's tyrosine kinase (Btk), in chronic lymphocytic leukemia (CLL) and B-non-Hodgkin lymphoma (B-NHL). ASCO Meeting Abstr 2012; 30(15 suppl): 8032.
38. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10(3): 262-7.
39. Carvajal RD, Tse A, Schwartz GK. Aurora kinases: New targets for cancer therapy. Clin Cancer Res 2006; 12(23): 6869-75.
40. Kollareddy M, Zheleva D, Dzubak P, Brahmkshatriya PS, Lepsik M, Hajduch M. Aurora kinase inhibitors: Progress towards the clinic. Invest New Drugs 2012; 30(6): 2411-32.
41. Babish, G. J., Bland, J., Desai A., Hall, J. A., Konda, V., Tripp, L. M. Protein kinase modulation by hops and Acacia products. EP1928248 (2008).
42. Liu Y, Gray NS. Rational design of inhibitors that bind to inactive kinase conformations. Nat Chem Biol 2006; 2(7): 358-64.
43. Hayess K, Benndorf R. Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase. Biochem Pharmacol 1997; 53(9): 1239-47.
44. Ward BC, Kavalukas S, Brugnano J, Barbul A, Panitch A. Peptide inhibitors of MK2 show promise for inhibition of abdominal adhesions. J Surg Res 2011; 169(1): e27-36.
45. Hur W, Velentza A, Kim S, Flatauer L, Jiang X, Valente D, et al. Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase. Bioorg Med Chem Lett 2008; 18(22): 5916-9.
46. Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. Proc Natl Acad Sci USA 1998; 95(20): 12022-7.
47. Slichenmyer WJ, Elliott WL, Fry DW. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol 2001; 28(5 Suppl 16): 80-5.
48. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 2005; 102(21): 7665-70.
49. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK, et al. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005; 102(31): 11011-6.
50. Chau CH, Chen KY, Deng HT, Kim KJ, Hosoya K, Terasaki T, et al. Coordinating Etk/Bmx activation and VEGF upregulation to promote cell survival and proliferation. Oncogene 2002; 21(57): 8817-29.
51. Zhang R, Xu Y, Ekman N, Wu Z, Wu J, Alitalo K, et al. Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factorinduced angiogenic pathway. J Biol Chem 2003; 278(51): 51267-76.
52. Pan S, An P, Zhang R, He X, Yin G, Min W. Etk/Bmx as a tumor necrosis factor receptor type 2-specific kinase: Role in endothelial cell migration and angiogenesis. Mol Cell Biol 2002; 22(21): 7512-23.
53. Holopainen T, Alpuche VL, Zheng W, Heljasvaara R, Jones D, He Y, et al. Deletion of the endothelial Bmx tyrosine kinase decreases tumor angiogenesis and growth. Cancer Res 2012; 72(14): 3512-21.
54. Tu T, Thotala D, Geng L, Hallahan DE, Willey CD. Bone marrow X kinase-mediated signal transduction in irradiated vascular endothelium. Cancer Res 2008; 68(8): 2861-9.
55. Robinson D, He F, Pretlow T, Kung HJ. A tyrosine kinase profile of prostate carcinoma. Proc Natl Acad Sci USA 1996; 93(12): 5958-62.
56. Mathews LA, Hurt EM, Zhang X, Farrar WL. Epigenetic regulation of CpG promoter methylation in invasive prostate cancer cells. Mol Cancer 2010; 9: 267.
57. Jiang T, Guo Z, Dai B, Kang M, Ann DK, Kung HJ, et al. Bidirectional regulation between tyrosine kinase Etk/Bmx and tumor suppressor p53 in response to DNA damage. J Biol Chem 2004; 279(48): 50181-9.
58. Yu L, Mohamed AJ, Simonson OE, Vargas L, Blomberg KE, Björkstrand B, et al. Proteasome-dependent autoregulation of Bruton tyrosine kinase (Btk) promoter via NF-kappaB. Blood 2008; 111(9): 4617-26.
59. Sherry MM, Reeves A, Wu JK, Cochran BH. STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. Stem Cells 2009; 27(10): 2383-92.
60. Fujisawa Y, Li W, Wu D, Wong P, Vogel C, Dong B, et al. Ligand-independent activation of the arylhydrocarbon receptor by ETK (Bmx) tyrosine kinase helps MCF10AT1 breast cancer cells to survive in an apoptosis-inducing environment. Biol Chem 2011; 392(10): 897-908.
61. Uckun FM, Dibirdik I, Qazi S, Vassilev A, Ma H, Mao C, et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Pololike kinase (PLK). Bioorg Med Chem 2007; 15(2): 800-14.
62. Guo L, Chen P, Zhou Y, Sun Y. Non-receptor tyrosine kinase Etk is involved in the apoptosis of small cell lung cancer cells. Exp Mol Pathol 2010; 88(3): 401-6.
63. Zhang Z, Zhu W, Zhang J, Guo L. Tyrosine kinase Etk/Bmx protects nasopharyngeal carcinoma cells from apoptosis induced by radiation. Cancer Biol Ther 2011, 11(7): 690-8.
64. Guo S, Sun F, Guo Z, Li W, Alfano A, Chen H, et al. Tyrosine kinase ETK/Bmx is up-regulated in bladder cancer and predicts poor prognosis in patients with cystectomy. PLoS One 2011; 6(3): e17778.
65. Guo L, Guo Y, Xiao S. Expression of Etk/Bmx tyrosine kinase in intrahepatic cholangiocarcinoma. J Surg Oncol 2008; 97(5): 428-32.
66. Guo L, Guo Y, Xiao S. Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1-and NF-kappaB-associated proteins in hepatocellular carcinoma. Oncology 2007; 72(5-6): 410-6.